These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 14732307)

  • 1. Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone.
    Anderegg TR; Jones RN
    Int J Antimicrob Agents; 2004 Jan; 23(1):6-10. PubMed ID: 14732307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of disk diffusion and MIC quality control parameters for AZD2563, a novel long-acting oxazolidinone.
    Anderegg TR; Jones RN;
    Diagn Microbiol Infect Dis; 2003 Jan; 45(1):73-6. PubMed ID: 12573554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro evaluation of AZD2563, a novel oxazolidinone, against 603 recent staphylococcal isolates.
    Anderegg TR; Biedenbach DJ; Jones RN
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2662-4. PubMed ID: 12121951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual gram-positive species.
    Jones RN; Biedenbach DJ; Anderegg TR
    Diagn Microbiol Infect Dis; 2002 Feb; 42(2):119-22. PubMed ID: 11858907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro antimicrobial activities of torezolid (TR-700), the active moiety of a new oxazolidinone, torezolid phosphate (TR-701), determination of tentative disk diffusion interpretive criteria, and quality control ranges.
    Brown SD; Traczewski MM
    Antimicrob Agents Chemother; 2010 May; 54(5):2063-9. PubMed ID: 20231392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disk diffusion test interpretive criteria and quality control recommendations for testing linezolid (U-100766) and eperezolid (U-100592) with commercially prepared reagents.
    Biedenbach DJ; Jones RN
    J Clin Microbiol; 1997 Dec; 35(12):3198-202. PubMed ID: 9399519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of a novel oxazolidinone, AZD2563, against randomly selected and multiresistant Gram-positive cocci.
    Johnson AP; Warner M; Livermore DM
    J Antimicrob Chemother; 2002 Jul; 50(1):89-93. PubMed ID: 12096011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro evaluation of AZD2563, a new oxazolidinone, tested against beta-haemolytic and viridans group streptococci.
    Anderegg TR; Biedenbach DJ; Jones RN
    J Antimicrob Chemother; 2002 Jun; 49(6):1019-21. PubMed ID: 12039896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of commercial dry-form broth microdilution panels for susceptibility testing of AZD2563, a new long-acting oxazolidinone.
    Jones RN; Anderegg TR; Biedenbach DJ
    Clin Microbiol Infect; 2003 Jun; 9(6):543-6. PubMed ID: 12848732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of AZD2563, a novel oxazolidinone, against Staphylococcus aureus strains with reduced susceptibility to vancomycin or linezolid.
    Howe RA; Wootton M; Noel AR; Bowker KE; Walsh TR; MacGowan AP
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3651-2. PubMed ID: 14576139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-anaerobic activity of AZD2563, a new oxazolidinone, compared with eight other agents.
    Ednie LM; Jacobs MR; Appelbaum PC
    J Antimicrob Chemother; 2002 Jul; 50(1):101-5. PubMed ID: 12096013
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxazolidinone susceptibility patterns for 2005: International Report from the Zyvox Annual Appraisal of Potency and Spectrum Study.
    Ross JE; Fritsche TR; Sader HS; Jones RN
    Int J Antimicrob Agents; 2007 Mar; 29(3):295-301. PubMed ID: 17239570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum and potency evaluation of a new oxazolidinone, linezolid: report from the SENTRY Antimicrobial Surveillance Program, 1998-2000.
    Mutnick AH; Biedenbach DJ; Turnidge JD; Jones RN
    Diagn Microbiol Infect Dis; 2002 May; 43(1):65-73. PubMed ID: 12052631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AZD2563, a novel oxazolidinone: definition of antibacterial spectrum, assessment of bactericidal potential and the impact of miscellaneous factors on activity in vitro.
    Wookey A; Turner PJ; Greenhalgh JM; Eastwood M; Clarke J; Sefton C
    Clin Microbiol Infect; 2004 Mar; 10(3):247-54. PubMed ID: 15008947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxazolidinone susceptibility patterns in 2004: report from the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations.
    Jones RN; Ross JE; Fritsche TR; Sader HS
    J Antimicrob Chemother; 2006 Feb; 57(2):279-87. PubMed ID: 16326811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zyvox Annual Appraisal of Potency and Spectrum program: linezolid surveillance program results for 2008.
    Jones RN; Ross JE; Bell JM; Utsuki U; Fumiaki I; Kobayashi I; Turnidge JD
    Diagn Microbiol Infect Dis; 2009 Dec; 65(4):404-13. PubMed ID: 19913683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AZD2563, a new oxazolidinone: bactericidal activity and synergy studies combined with gentamicin or vancomycin against staphylococci and streptococcal strains.
    Jones RN; Anderegg TR; Deshpande LM
    Diagn Microbiol Infect Dis; 2002 May; 43(1):87-90. PubMed ID: 12052634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of AZD2563, a novel oxazolidinone, against European Gram-positive cocci.
    Fluit AC; Schmitz FJ; Verhoef J; Milatovic D
    J Antimicrob Chemother; 2002 Aug; 50(2):271-6. PubMed ID: 12161411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of linezolid susceptibility test results as a surrogate for the susceptibility of Gram-positive pathogens to tedizolid, a novel oxazolidinone.
    Zurenko G; Bien P; Bensaci M; Patel HN; Thorne G
    Ann Clin Microbiol Antimicrob; 2014 Sep; 13():46. PubMed ID: 25238753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of linezolid against Gram-positive cocci isolated in French hospitals as determined by three in-vitro susceptibility testing methods.
    Muller-Serieys C; Drugeon HB; Etienne J; Lascols C; Leclercq R; Nguyen J; Soussy CJ
    Clin Microbiol Infect; 2004 Mar; 10(3):242-6. PubMed ID: 15008946
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.